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A B S T R A C T
The organic extract EB689, obtained from the stem of Abarema auriculata (Benth.) Barneby & 
J.W.Grimes, Fabaceae, commonly known as “saboeiro-ferro”, was chemically studied, as well 
as its influence over behavioral effects such as locomotion, emotionality and anxiety, after 
intra-peritonial administration were assessed. The open-field and elevated-plus maze were 
used in experiments divided into two stages. The first stage aimed for the identification of 
the main effects over behavior using a reduced number of animals against half-fold diluted 
doses of EB689.  The same variables were also tested in a second stage of the experiment 
using the non-lethal intra-peritoneal dose of 4.8 mg/kg in a larger number of animals. It was 
observed that EB689 clearly decreased locomotion, which was probably caused by internal 
hemorrhage causing hypovolemic shock. Although it is the first time lupeol and eucryphin 
are described in A. auriculata, it is still not clear if they are involved in the toxicology of 
A. auriculata. The undesirable effects of EB689 are better understood, the basis for further 
pharmacological assays aiming antitumor activity are supported.
© 2013 Brazilian Society of Pharmacognosy. Published by 
Elsevier Editora Ltda. 
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Introduction
Abarema auriculata (Benth.) Barneby & J.W.Grimes (crude extract 
also known as EB689) is a plant found in the Amazon rainforest 
that belongs to the Fabaceae family and is locally known as 
“saboeiro-ferro” (Salomão et al., 2007). The organic extract 
obtained from the stem of the plant, named here as EB689, 
showed a notable cytoxicity against prostate cancer cell lines 
(growth inhibition -32.66%; in Suffredini et al., 2006b), human 
central nervous system cancer cell lines (growth inhibition 
-24.69%; in Suffredini et al., 2007) and against head-and-neck 
tumor cell lines. They displayed significant growth inhibition, 
when compared to control groups (Ozi et al., 2011) in vitro. 
EB689 was selected amongst more than 1,300 plant extracts 
screened (Suffredini et al., 2006a, Younes et al., 2007). As there 
are no reports on the traditional use or toxic effects of the 
Open access under CC BY-NC-ND license. 
904 Daniela F. Gusmão et al. / Rev Bras Farmacogn 23(2013): 903-912
plant, it is imperative that information regarding its possible 
cytotoxic effects be evaluated. In the present study, the 
influence over locomotion, anxiety and emotionality in male 
mice was assessed after intraperitoneal (i.p.) administration 
of the crude extract. 
Previously, our group determined the lethal dose 50% and 
evaluated the influence of the extract over general activity 
(Gusmão et al., 2013) in an optimized protocol using few 
animals, with the purpose of avoiding unnecessary animal 
suffering. The present study, which is an extension of the 
previous one, aims to evaluate the influence of different doses 
of EB689 on multiple parameters related to anxiety, locomotion, 
and emotionality after intraperitoneal (i.p.) administration, 
over Balb-c male mice (Botham, 2004).
Materials and methods
Plants were collected in the Brazilian Amazon rainforest, under 
Brazilian Government (Environment Ministry) licenses (CGen/
MMa#12A/2008) for collecting genetic resources in protected 
areas of the Brazilian forests. Plants were collected in Manaus, 
AM, in the Igapó forest, (seasonally flooded forests from the 
Rio Negro Basin), in January 22 1999. The voucher specimen 
was deposited at UNIP Herbarium (A.A.Oliveira, 3353 (UNIP 
Herbarium)). Specimen was authenticated by Curator Prof. Dr. 
Mateus L. B. Paciencia.
Plant material
The stems of Abarema auriculata (Benth.) Barneby & J.W.Grimes, 
Fabaceae, were collected, dried in a ventilated drying oven 
(Fanem) at 40oC, and ground in a hammermill crusher 
(Holmes). About 545 g of the ground material was placed in 
a glass percolator (Kontes) where it was macerated for 24 h 
with 1.80 l of dichloromethane and methanol (1:1) (Suffredini 
et al., 2006b) (Merck), resulting in 26.56 g (4.87% yield) of crude 
extract. Solvents were evaporated under vacuum (Büchi) 
and were kept in a freezer (Revco) until use. The extract was 
suspended in almond oil for animal administration.
Assays
Extract fractionation and isolation of compound 
Organic extract EB689 (14.09 g) was solubilized in methanol 
(15 ml) and chloroform (10 ml), followed by the addition of 
water (20 ml). The solubilized extract was transferred to a glass 
column (2.5 cm diameter, 90 cm length). Chloroform (100 ml) 
was added to the column, and as the chloroform is heavier 
than the aqueous phase, it passes through the polar phase 
in an intimate contact eluting low polarity substances. The 
procedure was repeated once more. The chloroform extract 
was air evaporated, resulting in a dark-brown chloroform 
residue (RCHCl3) (2.63 g; 18.45% yield). The remaining solvent 
in the aqueous phase was evaporated. The aqueous phase 
was then subjected to a butanol partition, resulting in the 
production of a brown butanolic residue (RBuOH) (7.02 g; 
50.07% yield). The aqueous phase was lyophilized (RH2O) (4.44 
g; 31.51% yield). RCHCl3was subjected to a Sephadex LH20 
(22 g) column chromatography (CC) (2.5 cm diameter, 90 cm 
length) with 300 ml of hexane, 250 ml dichloromethane and 
200 ml methanol used to elute the column, resulting in FrHEX 
(653.0 mg; 4.63% yield), FrDCM (464.9 mg; 17.68% yield) and 
FrMeOH (1.51 g; 10.72% yield). FrHEX (219.5 mg; 1.56% yield) 
and FrDCM (147.6 mg; 1.05% yield) were further fractionated by 
CC using silica gel (60-200 μm particle size) eluted with solvent 
mixtures of increasing polarity such as n-hexane, ethyl acetate 
and methanol; this resulted in 28 and 27 fractions, respectively. 
Fractions were combined according to analytical thin layer 
chromatographic (TLC) similarity after visualization with 25% 
sulfuric acid followed by heating. As a result spinasterol was 
isolated (Gusmão et al., 2013). From 12-14FrHex the compound 
named lupeol was isolated after purification in preparative 
layer chromatography and Hex:AcOEt (9.5:0.5) as eluent. 
Lupeol (1): beige powder (5.2 mg). 1H NMR (CDCl3):G 0.77 
(Me-24, s), 0.79 (Me-28, s), 0.84 (Me-25, s), 0.96 (Me-27, s), 0.98 
(Me-23, s), 1.04 (Me-26, s), 1.69 (Me-30, s), 2.39 ( H-19, ddd J = 
11.16, 11.16, 5.71), 3.20 (H-3D, dd J = 11.42, 4.67), 4.58 (H-29a, m), 
4.70 (H-29b, m). 13C NMR (CDCl3): G 14.55 (C-27), 15.36 (C-24), 
15.98 (C-26), 16.11 (C-25), 18.01 (C-28), 18.32 (C-6), 19.31 (C-30), 
20.94 (C-11), 25.16 (C-12), 27.43 (C-2, 15), 27.99 (C-23), 29.86 
(C-21), 34.29 (C-7), 35.59 (C-16), 37.18 (C-10), 38.07 (C-13), 38.72 
(C-1), 38.86 (C-4), 40.01 (C-22), 40.85 (C-8), 42.84 (C-14), 43.00 
(C-17), 47.99 (C-19), 48.32 (C-18), 50.46 (C-9), 55.31 (C-5), 79.02 
(C-3), 109.31 (C-29), 150.98 (C-20). Comparison of the obtained 
results can be revised elsewhere (Mahato and Kundu, 1994).
Eucryphin (2) (10 mg). 1H NMR (CD3OD): G 1.28 (Me-Rham, 
d J = 6.16), 5.33 (H-1Rham, d J = 0.99), 6.22 (H-6, d J = 1.99), 
6.34 (H-8, d J = 1.79), 8.11 (H-2, s). 13C NMR (CDCl3): G 18.13 
(C-6´), 71.32 (C-4´), 71.76 (C-2´), 72.05 (C-5´), 73.68 (C-3´), 95.11 
(C-1´), 100.18 (C-8), 102.24 (C-6), 106.63 (C-10), 140.53 (C-3), 
148.11 (C-2), 159.46 (C-5), 163.59 (C-9), 166.3 (C-7), 178.86 (C-4). 
Comparison of the obtained results can be revised elsewhere 
(Tschesche et al., 1979). Li et al. (1996) proposed the structure 
of a compound isolated from Smilax glabra, which was named 
smiglanin. Smiglanin has an identical molecular structure of 
that proposed to eucryphin by Tschesche years before. In the 
present work we use eucryphin as the name of the identified 
molecule.
Fraction RBuOH was subjected to flash column chromatography 
(3.5 cm diameter and 25 cm length), using 60 g of C-18 silica 
as stationary phase and eluted with 400 ml of 15% acetonitrile 
(ACN) in acidified water with 0.1% trifluoroacetic acid (TFA), 500 
ml of 50% ACN in 0.1% TFA acidified water and 200 ml of MeOH 
(0.1% TFA). Three fractions were obtained from RBuOH, named: 
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Fr15%ACNRBuOH (2.18 g; 15.47% yield); Fr50%ACNRBuOH (4.64 
g; 32.93% yield); and FrMeOHRBuOH (194.8 mg; 1.38% yield). 
Three fractions were obtained from the C-18 chromatography 
of RH2O named: Fr15%ACNRH2O (2.62 g; 18.60% yield); 
Fr50%ACNRH2O (1.81 g; 12.85% yield); and FrMeOHRH2O (21.0 
mg; 0.15% yield). Five flavonones named neoastilbin, astilbin, 
isoastilbin, neoisoastilbin and engeletin were previously 
isolated from Fr15%ACNRBuOH of EB689 (Gusmão et al., 2013), 
their spectral information can be found elsewhere. The HPLC 
chromatogram at 254 nm fraction contains isolated eucryphin 
(2); it can be seen in Fig. 1. Eucryphin was isolated at 18% ACN, 
the LC/MS/MS (18-30% de ACN t0o30min, 30-50% ACN t30o40min, 
50%-100% ACN t40o50min.) chromatogram displayed the 
eucryphin containing fraction at negative mode, as well as its 
ESI- mass spectrum, the negative mode MS2 spectra of (2M-H)- 
and the negative mode MS2 spectra of (M-H)- can be seen in the 
supplementary material. Eucryphin (1 mg/ml) was dissolved 
in methanol, membrane-filtered (0.45 μm), and analyzed by 
LC/ESI-MSn. A Shimadzu HPLC System consisting of a CBM 20 
A, LC 20AD binary-pump, SPD 20A detector, a SIL 20AC auto 
sampler, and a C-18 Luna HPLC column, (5 μm, 250 mm x 4.6 
mm; Phenomenex) were used. The column was run at 40 °C. 
The mobile phase consisted of A: H2O w/0.1% CH3COOH; B: 
MeCN; isocratic 18% ACN for 30 min; flow rate: 1 ml/min. A 
Bruker Daltonics Esquire 3000 ion trap mass spectrometer, 
equipped with an electrospray ionization (ESI) source was used. 
Instrument control and data acquisition were performed using 
Esquire 5.2 software. The ion source temperature was 320 °C 
and capillary voltage was set at 4000V and end plate offset at 
500V. Nitrogen served as nebulizer gas regulated at 27 psi and 
at a flow rate of 7 l/min. The mass spectrometer was operated 
in full- scan, negative-ions mode.
Preparation of extract to be administered
EB689 was suspended in almond oil and the following doses 
were administered: 5 000, 2 500, 1 250, 625, 312.5, 156.3, 
78.1, 39.1, 19.5, 9.7, 4.8 mg/kg i.p. The extract was diluted 
in almond oil, due to its non-polar origin, and because it 
is compatible with human organism as well as for its non-
toxicity. The i.p. route was chosen due to the absence of 
bioavailability loss. Vehicle control group was assessed (0.1 
ml/10 g of almond oil) as well as a naïve group, which did 
not receive any treatment.
Animals
Male Balb-C mice (Mus domesticus) weighing 25-30 g were 
used; they were obtained from São Paulo University Medical 
School. After arrival in the laboratory, animals were housed 
in groups of five in microisolation cages (38 x 32 x 16 cm) 
with controlled room temperature (22 ± 2ºC), humidity 
(65-70%), and artificial lighting (12 h light/12 h dark cycle, 
lights on at 8 a.m.), and free access to Nuvilab® rodent chow 
(Nuvital Company, São Paulo, Brazil) and filtered water. 
The experiments began one week after the mice arrived 
to the lab for habituation to the new conditions. All the 
experiments done with mice were subjected and approved 
by the Ethic Committees (CEP/ICS/UNIP 025/08 and CaPPesq 
1109/090). 
Open field
The open field (OF) test used to assess the influence of the 
extract over emotionality and motility was built as early 
proposed (Broadhurst, 1960), adapted to the size of mice. 
The open-field used in the present study was a circular 
wooden box (40 cm in diameter and 50 cm high) with an 
open top and a floor divided into 19 squares. Illumination 
was provided by a room lamp of 100W (at the floor of 
apparatus 400 lx). Each animal was individually placed in 
the center of the arena of the OF, and parameters were 
measured over a period of 5 min in five sessions starting 
assessment 10-15, 30-35, 60-65, 120-125 and 180-185 min 
after the administration of the extract. Hand-operated 
counters were employed to count locomotion frequency 
(i.e., number of squares crossed with the four paws), rearing 
frequency (one unit of rearing corresponds to a standing 
position on the hindlimbs, with the trunk perpendicular 
to the floor, head tilted up and the forelimbs touching, 
or not, the walls of the arena with its forelegs in the air) 
and the number of fecal boli at the end of experiments. A 
chronometer was used to measure the immobility duration 
(i.e., total time in seconds without spontaneous movements, 
i.e., when head, trunk and limbs were still) and grooming 
duration (total time of washing movements over the head, 
licking the paws, fur licking, and tail/genital cleaning). To 
minimize the possible influences of circadian changes on 
OF, control and experimental animals were alternated. 
The device was cleaned with a 5% alcohol/water solution 
before placing the animals in it to eliminate the possible 
bias caused by odors left by the previous subject. The 
assays started at 1 p.m. and ended before 5 p.m., in order 
to prevent the circadian influences. 
Figure 1 - HPLC chromatogram of fraction 15% ACN BuOH 
from EB689 (obtained from Abarema auriculata), at 254 nm. 
(18-30% de ACN t0 o30min, 30-50% ACN t30 o40min, 50%-100% 
ACN t40 o50min.) 1. eucryphin; 2. neoastilbin; 3. astilbin; 4. 
isoastilbin; 5. neoisoastilbin; 6. engeletin. Identification and 
elucidation of flavonones 2 to 6 can be found elsewhere 
(Gusmão et al., 2013).
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Elevated-plus maze
The elevated-plus maze (EPM) is an apparatus first conceived 
by the British psychologist Sheila Handley’s group as a model 
to evaluate anxiety and it is one of the most used (Lapiz-Bluhm 
et al., 2008). The elevated plus-maze used was made of wood 
and had two open arms (23.5 cm × 8 cm) and two enclosed 
arms of the same size with 20 cm high walls; the apparatus 
was elevated 80 cm above the ground, it was placed in a sound-
proof room with room lamp of 100W (at the floor of apparatus 
400 lx). Basically, two strategies can be easily noticed: 
avoidance of the open arms while staying in the closed arm, 
and escaping behavior from the open arm directly to the closed 
arm (Pinheiro et al., 2007). In the present study, the maze was 
used to assess anxiety, and the animals were evaluated after 
being tested in the OF. Exploratory behavior was determined 
by the number of entries into the closed arms and the number 
of crosses in the center of the EPM. The animals were allocated 
in the center of the maze, which was previously cleaned with 
5% alcohol. The number of entrances in the open arm and in 
the closed arm, as well as the time remaining in each arm and 
the number of center crossing were measured. Observations 
were done at 15-20, 35-40, 65-70, 125-130 and 185-190 min 
after the administration of the extract and immediately after 
observation in the OF.
Experiment design
In order to investigate the effects of EB689 administration 
over mice we performed a two-stage experiment. At the first 
stage, the tendency to provoke alterations in anxiety and 
psychomotricity levels on mice after the administration of 
known doses of EB689 was assessed; this stage was performed 
with a reduced number of animals (n = 3 per group). Evaluation 
in open field and elevated-plus maze were done right after 
assessing general activity (results in Gusmão et al., 2013) The 
initial dose employed was 5,000 mg/kg and doses were half-
fold diminished according to lethality observed in at least one 
animal/dose previously reported by Gusmão et al. (2013). The 
second stage of the experiment was conducted using the non-
lethal dose (NLD) of 4.8 mg/kg, using ten mice/group. Mice were 
individually observed in the OF followed by the EPM test in 
stage 1, as shown in Fig. 2, but extracts were not tested in EPM 
in the second stage. Based on physiological issues, the assays 
started at 1 p.m. and ended before 5 p.m., in order to prevent 
the circadian influences.
Statistical analysis
Parametric measures were analyzed by two-way ANOVA (Zar, 
1999) followed by Bonferroni’s posttests (GrahpPad Prism 5.0). 
A probability of p <0.05 was considered significant to show 
differences among means.
Results
Results obtained from the first stage of the experiments 
in the OF can be seen in Table 1. Animals that received 
doses of 5 000 down to 625.0 mg/kg were deadly affected 
by i.p. administration of EB689, for the entire duration of 
the experiment. For that reason, the main effects of EB689 
on multiple parameters related to anxiety, locomotion 
and emotionality could in fact be observed after i.p. 
administration of doses 312.5 down to 4.8 mg/kg. Table 
1 shows the locomotion and rearing frequencies and the 
immobility time, as well as defecation and grooming 
parameters. Locomotion frequency suffers significantly by the 
treatment (F7;80 = 12.98; p < 0.001), as well as the interaction 
between treatment and time (F28;80 = 1.77; p < 0.05). It was 
observed that locomotion significantly decreased after i.p. 
administration of doses 312.5 down to 19.8 mg/kg in all 4th 
and 5th sessions (p < 0.01), excluding those sessions observed 
after administration of doses 9.8 and 4.8 mg/kg. Treatment 
(F7;79 = 3.34; p <0.01) showed to be the parameters that 
diminished rearing frequency after i.p. administration of 
doses 312.5 down to 19.8 mg/kg in all 5th sessions (p < 0.05), 
excluding those sessions observed after administration of 
doses 9.8 and 4.8 mg/kg. However, immobility time, grooming 
and defecation in treated animals did not exhibit significant 
alterations in relation to control group (p > 0.05).
Figure 2 - Experiment design diagram of the first and second stage. Behavioral effects of EB689 after intraperitoneal injection, 
in mice: time line related to the experimental design of first stage of experiments. OF, open field; EPM, elevated-plus maze.
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Open field evaluation stage 1
Ñocomotion frequency (Mean ± SEM)
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 116.30 ± 24.66 50.67 ± 25.18 20.67 ± 16.68 30.67 ± 12.44 10.33 ± 4.10 41.67 ± 17.36 62.33 ± 9.49 76.33 ± 14.84
session 2 98.67 ± 50.78 18.33 ± 5.78 13.67 ± 10.67 67.67 ± 12.25 74.00 ± 6.81 164.00 ± 21.78 64.67 ± 34.11 62.00 ± 10.07
session 3 91.67 ± 40.19 14.33 ± 2.33 26.67 ± 14.84 27.67 ± 11.26 18.00 ± 7.81 64.33 ± 27.69 68.33 ± 37.84 132.70 ± 25.39
session 4 167.70 ± 45.76 18.00 ± 6.51** 4.33 ± 1.20*** 12.00 ± 2.08** 4.67 ± 0.67*** 2.67 ± 1.33*** 69.33 ± 27.19 108.30 ± 28.90
session 5 178.70 ± 35.41 10.33 ± 7.97*** 8.33 ± 6.44*** 4.33 ± 1.20*** 3.67 ± 2.73*** 5.33 ± 4.37*** 110.30 ± 96.02 96.33 ± 25.99
Rearing frequency (Mean ± SEM)
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 0.00 ± 0.00 0.33 ± 0.33 0.50 ± 0.50 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.67 ± 0.67 0.33 ± 0.33
session 2 3.33 ± 3.33 1.00 ± 1.00 0.00 ± 0.00 0.33 ± 0.33 7.33 ± 6.36 0.00 ± 0.00 5.67 ± 1.20 0.33 ± 0.33
session 3 2.33 ± 2.33 0.00 ± 0.00 0.33 ± 0.33 0.00 ± 0.00 0.33 ± 0.33 0.670.33 13.33 ± 10.48 7.67 ± 5.78
session 4 7.33 ± 4.10 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 8.00 ± 5.69 8.67 ± 7.22
session 5 20.00 ± 12.10 0.33 ± *0.33 0.00 ± *0.00 0.00 ± *0.00 0.00 ± *0.00 0.00* ± 0.00 9.00 ± 9.00 5.67 ± 5.17
Defecation
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 0.00 ± 0.00 0.00 ± 0.00 0.50 ± 0.50 0.67 ± 0.67 0.33 ± 0.33 0.33 ± 0.33 0.00 ± 0.00 0.33 ± 0.33
session 2 0.67 ± 0.33 0.33 ± 0.33 0.00 ± 0.00 0.00 ± 0.00 0.33 ± 0.33 0.67 ± 0.33 0.67 ± 0.33 0.67 ± 0.33
session 3 1.00 ± 0.58 0.00 ± 0.00 0.67 ± 0.33 0.33 ± 0.33 0.33 ± 0.33 0.33 ± 0.33 0.33 ± 0.33 1.00 ± 0.58
session 4 1.00 ± 0.58 0.00 ± 0.00 0.00 ± 0.00 0.33 ± 0.33 0.67 ± 0.67 0.00 ± 0.00 1.00 ± 0.58 0.33 ± 0.33
session 5 0.67 ± 0.67 0.00 ± 0.00 0.67 ± 0.33 0.00 ± 0.00 0.33 ± 0.33 0.00 ± 0.00 1.00 ± 0.58 0.33 ± 0.33
Grooming
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 0.33 ± 0.33 0.33 ± 0.33 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.67 ± 0.67 0.00 ± 0.00
session 2 2.67 ± 2.19 0.67 ± 0.67 0.00 ± 0.00 0.33 ± 0.33 4.00 ± 1.53 4.00 ± 3.00 2.67 ± 2.19 1.33 ± 0.88
session 3 1.00 ± 0.58 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 3.33 ± 2.85 2.33 ± 2.33 2.33 ± 1.45
session 4 1.33 ± 0.33 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.67 ± 0.67 3.33 ± 2.85
session 5 3.00 ± 1.53 2.33 ± 2.33 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.67 ± 0.67 9.67 ± 5.55
Immobility time
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 82.33 ± 44.18 159.30 ± 66.23 236.00 ± 29.0 249.00 ± 10.82 241.30 ± 10.84 238.70 ± 17.34 137.70 ± 50.716 76.33 ± 41.37
session 2 182.7 ± 44.54 189.00 ± 47.96 259.30 ± 14.85 202.30 ± 26.30 93.67 ± 10.20 116.00 ± 39.00 169.00 ± 72.062 125.00 ± 13.58
session 3 176.00 ± 22.12 154.70 ± 77.20 215.00 ± 45.35 266.70 ± 13.64 243.30 ± 16.90 250.30 ± 39.94 163.70 ± 66.356 61.33 ± 20.84
session 4 42.67 ± 31.44 253.30 ± *24.01 284.70 ± **4.63 278.70 ± **10.11 254.30 ± *12.44 296.70 ± ***2.85 210.70 ± 25.828 55.33 ± 16.91
session 5 91.33 ± 38.89 273.70 ± 19.33 264.00 ± 27.50 290.70 ± *1.76 272.00 ± 15.89 194.70 ± 97.44 184.30 ± 84.175 114.00 ± 38.55
Table 1
Locomotion and rearing frequencies (units), immobility time (seconds), grooming behavior (units) and defecation (units), open 
field parameters in the first stage of experiments (n = 3), after intraperitoneal administration of different doses of EB 689, 
obtained from Abarema auriculata. Five sessions of five minutes each were assessed at 15, 30, 60, 120 and 180 minutes after 
administration of the extract. Data are presented as mean ± SEM, calculated by two way ANOVA followed by Bonferroni test;  
*(p < 0.05), **(p < 0.01) and ***(p < 0.001), in relation to control group.
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Figure 3 - Open field behavior of mice (n = 10/group) in the second stage of experiments after administration of 4.8 mg/kg of 
EB 689 obtained from Abarema auriculata, and diazepam 1 mg/kg, via intraperitoneal injection. Session 1 = 10-15 min, session 
2 = 30-35 min, session 3 = 60-65 min, session 4 = 120-125 min and session 5 = 180-185 min. Two way ANOVA followed by 
Bonferroni test. *p < 0.05 in relation to control group; #p < 0.05 in relation to control naïve group.
Fig. 3 shows the results observed in the second stage of 
the experiments, and it’s relation to the results of OF (n = 
10), after administration of the non-lethal dose of 4.8 mg/
kg, in comparison to administration of diazepam 1 mg/kg. 
Considering locomotion frequency, treatment (F3;140 = 14.69; p 
< 0.001; 12.55% influence on the total variance) and time (F4;140 
= 23.65; p < 0.0001; 26.93% influence on the total variance) have 
significantly affected the results, as well as did the interaction 
(F12;140 = 3.49; p < 0.0001; 11.94% of total variance). Statistical 
differences in locomotion could be observed in the group 
treated with EB689, particularly at the 4th and 5th sessions. 
Treatment accounts for 15.19% of the total variance in rearing 
frequency and is considered extremely significant (F3;140 = 
10.24; p < 0.001) and interaction between treatment and time 
accounts for 11.20% of total variance (F12;140 = 1.89; p < 0.05). 
Alterations in rearing were observed after administration 
of 1 mg/kg diazepam, compared to vehicle control group. 
Differently from stage 1 results, immobility time increased 
in stage 2: Treatment (F3;140 = 18.36; p < 0.0001; 19.50% of the 
total variance), time (F4;140 = 8.54; p < 0.001; 12.10% of the 
total variance) and interaction between factors (F12;140 = 3.48; 
p < 0.001; 14.81% of the total variance). Differences in defecation 
could be observed between naïve control and EB689 groups (p 
< 0.05), and treatment was considered extremely significant 
(F3;140 = 5.45; p < 0.001; 8.83% of the total variance), as well as 
did time (F4;140 = 2.53; p < 0.001; 5.46% of the total variance). No 
significant differences were observed in grooming (p > 0.05).
Table 2 presents the results obtained in the elevated-plus 
maze after treatments. Treatment is considered extremely 
significant over the number of entrances in the open arm 
(F7;80 = 10.50; p < 0.001; accounting for 36.24% of the total 
variance) as well as the effect of treatment vs. time (F28;80 = 
1.64; p < 0.05; accounting for 22.64% of the total variance). 
On the other hand, time did not significantly account for the 
total variance (p > 0.05). Treatment accounts for most of the 
variance and the effect is considered extremely significant 
(F7;80 = 16.29; p < 0.001; 45.36% of the total variance) over the 
number of entrances in closed arms, time accounts for some 
of the variance and is considered significant (F4;80 = 3.60; p 
< 0.01; 5.73% of the total variance) and 4th and 5th sessions 
of groups treated with doses 312.5 down to 19.8 mg/ml 
showed an elevated tendency of preferring the closed arms 
(p < 0.001). All five sessions of groups treated with the last 
lower doses seemed to behave as control group (p > 0.05). In 
relation to the time spent in closed arms, treatment (F7;80 = 
10.07; p < 0.001; 28.91% of the total variance) and interaction 
between treatment and time (F28;80 = 3.18; p < 0.001; 36.53% 
of the total variance) influenced the alterations. Specifically 
the 4th sessions of groups treated with doses 312.5 down to 
19.8 mg/ml (p < 0.05) and session 1 of the group treated with 
doses 39.1 mg/ml. No significant differences were observed 
in the groups treated with doses 9.8 and 4.8 mg/ml nor 
significant differences were observed in the time spent in 
open arms (p > 0.05). 
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Anxiety Indexes
Entries in open arms
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 1.33 ± 0.88 0.00 ± 0.00 0.00 ± 0.00 0.33 ± 0.00 2.00 ± 2.00 0.00 ± 0.00 5.33 ± 2.85 0.33 ± 0.33
session 2 4.33 ± 3.84 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 2.67 ± 0.88 0.33 ± 0.33 4.33 ± 1.76 1.67 ± 1.67
session 3 5.00 ± 2.65 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 1.00 ± 1.00 0.00 ± 0.00 1.33 ± 0.88 11.0 ± 5.13
session 4 6.33 ± 3.18 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 7.67 ± 4.10 4.00 ± 2.52
session 5 7.00 ± 1.16 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 3.33 ± 2.40 9.33 ± 0.33
Entries in closed arms
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 8.33 ± 1.86 3.67 ± 2.67 1.00 ± 0.00 2.67 ± 0.88 5.33 ± 2.33 1.67 ± 0.33 11.00 ± 1.53 10.67 ± 3.53
session 2 6.67 ± 2.85 1.67 ± 0.33 1.00 ± 0.00 1.00 ± 0.00 6.00 ± 0.58 8.33 ± 0.33 9.33 ± 1.20 5.00 ± 2.65
session 3 6.00 ± 3.22 1.67 ± 0.67 1.00 ± 0.00 1.00 ± 0.00 2.67 ± 1.67 3.00 ± 1.16 4.33 ± 1.20 6.67 ± 1.45
session 4 11.33 ± 0.88 0.67 ± ***0.33 1.00 ± ***0.00 1.00 ± ***0.00 1.00 ± ***0.00 1.00 ± ***0.00 8.33 ± 3.18 5.00 ± 1.00
session 5 10.33 ± 3.33 1.00 ± **0.00 1.00 ± **0.00 1.00 ± **0.00 1.00 ± **0.00 0.67 ± **0.33 4.33 ± 3.84 4.33 ± 1.33
Time spent in open arms
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 16.33 ± 12.99 0.00 ± 0.00 0.00 ± 0.00 4.00 ± 4.00 12.33 ± 12.33 0.00 ± 0.00 67.00 ± 42.19 1.67 ± 1.67
session 2 76.3 ± 373.35 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 34.00 ± 15.62 3.00 ± 3.00 48.33 ± 22.51 75.33 ± 75.33
session 3 72.33 ± 45.74 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 19.67 ± 19.67 0.00 ± 0.00 12.00 ± 6.43 167.30 ± 78.84
session 4 103.30 ± 53.49 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 110.70 ± 57.98 99.67 ± 71.75
session 5 139.30 ± 32.46 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 200.00 ± 100.00 0.00 ± 0.00 153.70 ± 86.68 230.70 ± 46.37
Time spent in closed arms
control 0.3 ml/30 g 312.5 mg/kg 156.3 mg/kg 78.1 mg/kg 39.1 mg/kg 19.8 mg/kg 9.8 mg/kg 4.8 mg/kg
session 1 199.00 ± 75.08 300.00 ± 0.00 294.00 ± 6.00 296.30 ± 3.67 12.33* ± 12.33 300.00 ± 0.00 228.00 ± 47.57 299.00 ± 1.00
session 2 208.30 ± 80.92 300.00 ± 0.00 300.00 ± 0.00 300.00 ± 0.00 34.00 ± 15.62 295.00 ± 5.00 260.30 ± 30.33 228.30 ± 71.67
session 3 217.30 ± 56.61 300.00 ± 0.00 300.00 ± 0.00 300.00 ± 0.00 280.30 ± 19.67 300.00 ± 0.00 283.00 ± 8.89 132.00 ± 79.78
session 4 111.70 ± 34.65 300.00* ± 0.00 300.00* ± 0.00 300.00* ± 0.00 300.00* ± 0.00 300.00* ± 0.00 189.00 ± 58.59 201.70 ± 71.93
session 5 160.00 ± 30.12 300.00 ± 0.00 300.00 ± 0.00 300.00 ± 0.00 300.00 ± 0.00 200.00 ± 100.00 169.30 ± 88.73 70.67 ± 44.28
Table 2
Elevated plus-maze anxiety indexes obtained from intraperitoneal administration of EB689 to male Balb-c mice at different 
half-doses of 312.5 down to 4.8 mg/kg, and observed for 5 min in sessions of 15, 30, 60, 120 and 180 min after administration. 
Results are given in number of entries in closed or open arms and amount of time spent in open or closed arms. Data are 
presented as mean  ± SEM, calculated by two way ANOVA followed by Bonferroni test; *(p < 0.05), **(p < 0.01) and ***(p < 0.001).
Discussion
The open field test was developed to track alterations in 
emotionality in lab rodents. The measurement was stated as 
the amount of defecation of an emotional rodent compared 
to a non-emotional rodent, where the emotional rodent tends 
to defecate more in the apparatus (Hall, 1934 cited by Prutt 
and Belzung, 2003). Historically, OF defecations and activity 
has been used to assess emotionality and fearfulness (Hall, 
1934) and also to analyze for hyperactivity and exploratory 
behaviors. Usual parameters for rodent behavior would be that 
the number of fecal boli deposited, as well as their activity 
pattern, vary in relation to the levels of fear and emotional 
reactivity; where a large number of boli and little activity 
indicate a fearful individual. Also, rodents tend to avoid brightly 
illuminated novel open spaces and the Open Field would work 
as an anxiogenic stimulus, allowing for the development of 
anxiety related locomotor activity - and exploratory behaviors, 
resulting in the approach-avoidance conflict. The intensity of 
locomotion can be related to an anxiety-like or anxiolytic-like 
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effect promoted by some drug, and in the present report, it 
helped in the establishment of a behavioral pattern related 
to the administration of EB689. The first exposure of the 
animals to the device has a more significant emotional 
and locomotor component than the subsequent exposures 
(Batatinha et al., 1995; Lazarini et al., 2000; Massoco et al., 
1995; Moniz et al., 1994), although controversial (Carobrez 
and Bertoglio, 2005), which may lead to habituation. In the 
present work, no significant differences in defecation were 
observed during the first stage of experiments. This may 
indicate that mice receiving treatment were not influenced 
by EB689 over fearfulness or emotionality parameters. The 
analysis of locomotive behaviors showed that control groups 
followed an usual response to emotionality in response to 
a novel environment, as animals got used to the apparatus 
after 1st session. Locomotion in open field significantly 
decreased after treatment, however, after lower doses of 
EB689, animals moved more across the squares after the 
administration in a dose-dependent relationship. After the 
4th session, the treatment group showed improvement in 
locomotive behaviors when compared to the control group, 
which happened 120 min after i.p. administration of 9.8 mg/
kg of EB689. A similar pattern of behavior was observed for 
both rearing and immobility time. In the second stage of 
experiment, diazepam was introduced as reference drug. 
Then, mice were observed after the administration of a non-
lethal dose (4.8 mg/kg) of EB689 and the administration of 1 
mg/kg diazepam. Locomotion was clearly impaired by the 
extract administered, misleading the usual square crosses 
pattern seen to the other three groups. EB689 administration 
significantly showed reduced number of square crosses (in an 
inversely proportional relationship) and increased immobility 
time (in a direct relationship), maybe due to a sedative effect. 
It was observed the anxiolytic activity related to diazepam 
in the first session, but no alterations related to EB689. It is 
possible that more than 120 min are needed for the extract 
to carry out its effect. Prutt and Belzung (2003) proposed 
that rearing frequency diminishes after the administration 
of lower doses of diazepam to rats, but to Balb-c mice we 
observed that rearing frequency was significantly increased. 
Apparently, rearing frequency decreases after EB689 
administration, in relation to naïve mice, but no significance 
was observed. The significant alteration in defecation caused 
by EB689 in the second session may indicate a decrease in 
emotionality, but this result is not in agreement to the first 
stage of experiments and it remains inconclusive so far. 
As the first stage of experiments is more indicative than 
conclusive, the second stage of the experiment tends to 
support a more conclusive approach to determine the real 
influence of EB689 over mice.
Elevated-plus maze was used to assess anxiety effects 
of treatments in the first stage of the experiments. Briefly, 
an increase in open arm activity duration reflects anti-
anxiety - or anxiolytic-like - behavior over the approach-
avoidance conflict well established for EPM (Walf and Frye, 
2007; Carobrez and Bertoglio, 2005). In the present work, EPM 
analysis showed that animals remained longer in closed arms 
in a clear choice for the closed over the open arms, both for 
treated and control animals. It seems that EB689 does not 
influence the conflict between approach and avoidance, once 
animals did chose the closed arms as a normal expression 
of anxiety-like avoidance behavior. It was observed that 
although treated animals chose the closed arms, the number 
of center crosses was low, indicating that animals did not 
explore whatsoever. The results are in accordance with 
OF. On the other hand, this phenomenon was observed in 
the group that received 4.8 mg/kg, although the tendency 
was not statistically significant. These results bolster our 
findings. After the administration of doses 312.5 mg/kg 
down to 4.8 mg/kg there was a dose-dependent recovery 
of all parameters, when compared to the control. EPM was 
not assessed in the second stage of experiments, but only 
OF. Although OF and EPM are adequate and traditionally 
effectiv methods for the evaluation of possible influences of 
a treatment over locomotion, anxiety and emotionality; as it 
was made in the present work, further specific in vivo tests 
should be performed in order to refine the pharmacology and 
toxicology of EB689. The pronounced effects caused by the i.p. 
administration of the extract have been understood so far.
At the necropsy, it was observed the presence of 
hemorrhages at all administered doses, except for the non-
lethal dose, which led us to disregard sedation as a possible 
effect of EB689. Thus, a relationship between the OF and EPMc 
signs first observed with hemorrhagic shock could be made. 
Hypovolemic shock refers to a medical or surgical condition 
in which rapid fluid loss results in multiple organ failure due 
to inadequate circulating volume and subsequent inadequate 
perfusion. Most often, hypovolemic shock is secondary to 
rapid blood loss. In this case, a general weakness, cyanosis, 
rapid breathing followed by a reduced breathing and the 
activation of the sympathetic autonomous nervous system 
occurs previous to death. The toxicity of EB689 over the 
intestine endothelium may be causing internal hemorrhage 
and pain, leading to hypovolemic shock. Maybe this could 
be the main cause of the lack of immobility in OF and EPM, 
misleading any interpretation of parameters related to anxiety 
and/or emotionality. Ubiquitously, there are plants interfering 
in bleeding, such as Gingko (Gingko biloba), excess garlic (Allium 
sativum), ginger (Zingiber officinale), ginseng (Panax spp.), horse 
chestnut (Aesculus hyppocastanum), turmeric (Curcuma longa) 
and white willow (Salix alba), affecting clotting in one way or 
another (http://umm.edu/health/medical/altmed/condition/
hemophilia, accessed in 11/10/2013). As A. auriculata is now 
being introduced to the light of pharmacology and chemistry, 
its chemical composition has not been dilucidated so far; for 
that reason, it is still hard to propose a relationship between 
bleeding and the compounds that have been isolated.
Although lupeol and eucryphin were isolated from 
EB689, they were not tested in the toxicological assay. 
Further recollection of the plant species shall be made in 
order to perform in vivo evaluations of isolated compounds. 
Nonetheless, lupeol is widely studied in terms of biological or 
pharmacological activities, particularly as anticancer agents 
and as cytotoxic for tumor cell lines, as can be seen elsewhere. 
On the other hand, eucryphin has been poorly studied. Han 
et al. (1998) described that eucryphin enhanced lypolysis in 
rat fat cells. Also, Kimura and colleagues (2007) reported that 
eucryphin, isolated from Astilbe species, is traditionally used 
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to heal cuts and insect bites. Sumiyoshi and Kimura (2010) 
have described the influence of eucryphin (2) over burn wound 
healing and have reported that eucryphin would interfere with 
IL-1beta, MCP-1, VEGF, and TGF-beta1 levels in exudates from 
wounds; and increased the expression of VEGF, TGF-beta1, 
and HIF-1alpha of keratinocytes. Although such biological 
activities were reportedly associated to eucryphin there is no 
support that correlates such findings with the toxicity profile 
here reported. 
EB689 was selected from a biological screening aiming to 
the identification of cytotoxic Brazilian Amazon plant extracts 
against cancer cell lines. In the present work, it was observed 
that EB689 significantly decreased locomotion in mice and 
that may be caused by an evident internal intestinal bleeding 
result of i.p. administration of the extract. It is unlikely that 
lupeol (1) and eucryphin (2) – here described for the first 
time as constituents of A. auriculata - could be involved in 
the toxicology of A. auriculata. The effects of EB689 have been 
further elucidated, and they make up the basis for further 
pharmacological assays aiming towards the analysis of 
antitumor activity.
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